Mangalam Drugs and Organics Faces Intense Selling Pressure Amid Prolonged Decline

Sharp Decline in Daily and Weekly Performance

On 28 Nov 2025, Mangalam Drugs and Organics recorded a day change of -4.98%, significantly underperforming the Sensex, which posted a marginal gain of 0.08%. This decline is part of a broader trend, with the stock showing a one-week performance of -39.31%, while the Sensex gained 0.65% over the same period. The stark contrast highlights the stock’s vulnerability amid a relatively stable market environment.

Prolonged Downtrend and Consecutive Losses

The stock has been on a losing streak for nine consecutive trading days, during which it has shed approximately 54.58% of its value. This sustained fall reflects a lack of buying interest and mounting selling pressure, which has pushed the stock to its lowest levels in a year. The opening price today was Rs. 28.07, matching the day’s low, indicating no recovery or intra-day buying support.

Volatility and Trading Range

Mangalam Drugs and Organics exhibited high intraday volatility, calculated at 1217.84% based on the weighted average price. Despite this volatility, the stock traded within a narrow range, opening and closing at Rs. 28.07, which underscores the dominance of sellers and the absence of buyers willing to step in at current price levels.

Long-Term Performance Comparison

Over longer time horizons, the stock’s performance remains deeply negative. The one-month return stands at -56.58%, three months at -62.11%, and one year at -73.79%. Year-to-date figures show a decline of -75.79%, while the three-year and five-year performances are -78.96% and -81.16%, respectively. Over a decade, the stock has lost over 91% of its value. In contrast, the Sensex has delivered positive returns across all these periods, including a 10-year gain of 228.33%, highlighting the stark divergence between the broader market and Mangalam Drugs and Organics.

Technical Indicators Reflect Bearish Momentum

The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained bearish momentum and a lack of short-term or long-term support levels. The gap down opening today further emphasises the negative sentiment prevailing among investors.

Sector and Industry Context

Mangalam Drugs and Organics operates within the Pharmaceuticals & Biotechnology sector, which has generally shown resilience and growth in recent years. However, the company’s stock performance has diverged sharply from sector trends, underperforming by 5.12% today relative to its peers. This divergence may reflect company-specific challenges or market concerns that have not affected the broader industry.

Market Capitalisation and Investor Sentiment

The company’s market capitalisation grade indicates a relatively modest size within its sector. The persistent selling pressure and absence of buyers suggest that investor confidence is currently low, with market participants possibly reacting to fundamental or operational uncertainties. The continuous decline and lack of recovery attempts point to distress selling, where shareholders may be exiting positions to limit further losses.

Implications for Investors

The ongoing decline and extreme selling pressure in Mangalam Drugs and Organics highlight significant challenges for current and prospective investors. The absence of buyers and the stock’s failure to find support at multiple price levels suggest that market participants are cautious or pessimistic about the company’s near-term prospects. Investors should carefully analyse the underlying factors contributing to this trend and consider the broader sector dynamics before making decisions.

Summary of Key Metrics

To summarise, Mangalam Drugs and Organics has recorded:

• A fresh 52-week low of Rs. 28.07 reached today


• A daily loss of -4.98%, with no intra-day recovery


• A nine-day consecutive decline resulting in a cumulative loss of -54.58%


• Negative returns across all major time frames, including -75.79% year-to-date


• Trading below all major moving averages, indicating sustained bearish momentum


• Underperformance relative to the Sensex and sector peers

These data points collectively signal a distressed stock environment, with sellers dominating the order book and buyers absent from the market.

Looking Ahead

While the Pharmaceuticals & Biotechnology sector continues to attract investor interest due to its growth potential, Mangalam Drugs and Organics’ current market behaviour suggests that it is facing company-specific headwinds. Market participants will be closely monitoring any developments that could alter the stock’s trajectory, including operational updates, financial results, or sector-wide shifts.

For now, the stock remains under intense selling pressure, and investors should exercise caution and conduct thorough due diligence before considering exposure to Mangalam Drugs and Organics.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →